Advances in psoriasis treatment.
Schön
Michael P
MP
Rudolf Virchow Centre, DFG Research Centre for Experimental Biomedicine and Department of Dermatology, University of Würzburg, 97078 Würzburg, Germany. michael.schoen@virchow.uni-wuerzburg.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018925:Chemokines / Q000502:physiology; D016207:Cytokines / Q000502:physiology; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000911:Antibodies, Monoclonal; D018925:Chemokines; D016207:Cytokines; D003879:Dermatologic Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab